Latest Regulatory News

Contact Energy reported a 12% rise in EBITDAF to $404 million for 1H25, driven by new geothermal assets and strategic contracts, while net profit fell 7% due to market volatility and acquisition costs.

Carly Holdings Limited has agreed to merge its car subscription operations with Carbar Holdings in a $3.8 million deal, aiming to create a larger, more competitive player in Australia’s growing car subscription sector.

Many Peaks Minerals Limited has amended its previous ASX announcement on auger sampling at the Ferké Gold Project to enhance regulatory compliance, while continuing to advance exploration with diamond drilling and planned air core and RC programs.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

Macarthur Minerals Limited reported a comprehensive loss of AUD 252,771 for Q4 2024, marking a sharp reversal from the prior year's profit. The company is navigating reduced exploration spending and strategic asset sales while facing ongoing funding challenges.

Scorpion Minerals Limited has had its trading suspension lifted following an announcement about a potential joint venture and capital raising, signaling renewed market activity.

BSA Limited has temporarily paused trading of its securities, signaling potential significant developments. Investors await further details to understand the implications.

Siren Gold has restarted drilling at its Sams Creek Project in New Zealand, aiming to expand its 824,000-ounce gold resource by targeting deeper porphyry structures and fold hinges. The company plans a focused drilling campaign and mining study in 2025 to unlock further value.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.